Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

End-of-day quote. End-of-day quote NATIONAL STOCK EXCHANGE OF INDIA - 04/28
3403.95 INR   +0.65%
04/21DJIndia Shares Fall For Fifth Straight Session
04/08 DR REDDY LABORA : and its subsidiary Promius PharmaTM announce the f..
04/07 DR REDDY LABORA : and Its Subsidiary Promius PharmaTM Announce the F..
News SummaryMost relevantAll newsSector news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

03/05/2013 | 04:15am US/Eastern

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at +91-40-66834297
Saunak Savla at +91-40-49002135
Milan Kalawadia (USA) at +1 908-203-4931

S Rajan at +91-40-49002445

distributed by
React to this article
04/21 DR REDDY LABORATORIES : Banks on acquisitions for growth
04/21DJIndia Shares Fall For Fifth Straight Session
04/18 DR REDDY LABORATORIES : and Its Subsidiary Promius Pharma Files 3 NDAs With the ..
04/16 TAXUS CARDIUM PHARMACEUTICALS : Announces Agreement With Dr. Reddy's Laboratorie..
04/12 Number of usfda inspections in last seven years and form 483 issued
04/10 DR REDDY LABORATORIES : Sees india sales growing 20% on new product launches
04/10 DR REDDY LABORATORIES : and Its Subsidiary Promius Pharma Files 3 NDAs With the ..
04/08 DR REDDY LABORATORIES : Drl ties up with taxus cardium
04/08 DR REDDY LABORATORIES : . Reddy's Lab, Promius Pharma announces filing of three ..
04/08 DR REDDY LABORATORIES : and its subsidiary Promius PharmaTM announce the filing ..
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes